Is HeartBeam, Inc. (BEAT) a Buy, Sell, or Hold?
HeartBeam, Inc.
NASDAQ:BEAT
$0.6601 USD
$0.1 (17.71%)
- Volume
- 2.3M
- Average Volume
- 1.01M
- Market Capitalization
- $22.74M
- P/E Ratio
- -1.16
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $4.00
- Year Low
- $0.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.74
| Source | Headline |
|---|---|
|
HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device
[url="]HeartBeam, Inc.[/url] (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today an gurufocus.com - 2026-07-14 08:00:00 |
|
Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios
Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach. zacks.com - 2026-07-07 10:31:24 |
|
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule. businesswire.com - 2026-06-30 07:00:00 |
|
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition. businesswire.com - 2026-06-24 16:05:00 |
|
HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
[url="]HeartBeam, Inc.[/url] (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today an gurufocus.com - 2026-06-02 08:00:00 |
|
HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home. businesswire.com - 2026-06-02 07:00:00 |
|
HeartBeam (BEAT) Upgraded to Buy: Here's What You Should Know
HeartBeam (BEAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2026-05-27 13:01:19 |
|
HeartBeam Reports First Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports First Quarter 2026 Results. businesswire.com - 2026-05-13 16:01:00 |
|
HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic. businesswire.com - 2026-05-11 08:31:00 |
|
HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice. businesswire.com - 2026-05-07 08:31:00 |
|
HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time. businesswire.com - 2026-04-30 08:31:00 |
|
Insider Buying: HeartBeam (NASDAQ:BEAT) Director Purchases $600,000.00 in Stock
HeartBeam, Inc. (NASDAQ: BEAT - Get Free Report) Director Mark Strome acquired 750,000 shares of the firm's stock in a transaction dated Thursday, April 16th. The stock was bought at an average price of $0.80 per share, with a total value of $600,000.00. Following the acquisition, the director directly owned 3,650,000 shares in the company, valued defenseworld.net - 2026-04-19 04:36:55 |
|
HeartBeam Announces Closing of $10 Million Public Offering of Common Stock
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Closing of $10 Million Public Offering of Common Stock. businesswire.com - 2026-04-16 16:05:00 |
|
Head to Head Contrast: HeartBeam (NASDAQ:BEAT) versus Enovis (NYSE:ENOV)
HeartBeam (NASDAQ: BEAT - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends. Volatility and Risk HeartBeam has a beta of -0.63, defenseworld.net - 2026-04-15 02:26:50 |
